Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Multi-Site Study of COVID-19 Patients Utilizing Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay
Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States Study May Inform Recommendations for COVID-19 Care, New Strategies for Treatments SOUTH SAN FRANCISCO, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an
View HTML
Toggle Summary Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform
iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Screening of Critical Populations Under Way , Capacity of Up to 6,000 Tests Per Day on Single Instrument
View HTML
Toggle Summary New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System
Fluidigm to Be Exclusive Distributor for Bethyl Antibodies for Use with Imaging Mass Cytometry Providing Researchers with Expanded Capabilities in Interrogating the Tissue Microenvironment SOUTH SAN FRANCISCO, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an
View HTML
Toggle Summary Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Test for COVID-19
Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per Day Easy-to-Administer Saliva Test Would Eliminate Need for Invasive Nasopharyngeal Swab High-Throughput Assay Developed in Collaboration with Washington University School of Medicine SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19
Study Suggests That Type I IFN Deficiency in the Blood Could Help Define a High-Risk Population SOUTH SAN FRANCISCO, Calif. , May 19, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
View HTML
Toggle Summary Fluidigm to Present at Upcoming Health Care Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite , President and Chief Executive Officer, and Vikram
View HTML
Toggle Summary Fluidigm Announces First Quarter 2020 Financial Results
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for Ultrahigh-Throughput COVID-19 Tests on the BioMark platform Maxpar Direct Immune Profiling Assay powering large
View HTML
Toggle Summary Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services
Custom Projects and Consultation from Experimental Panel Design to Data Analysis              Providing Instrument Access Prior to Purchase Decision and Much‑Needed Capacity for Customers Affected by COVID-19 Related Laboratory Closures              New Collaboration via Therapeutic Insights
View HTML
Toggle Summary OU Medicine, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation File for FDA Emergency Use Authorization for COVID-19 Detection Test Utilizing Fluidigm Technology
Expediting Treatment of COVID-19 Patients and Enhancing Testing Resources for Caregivers in Oklahoma Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents SOUTH SAN FRANCISCO, Calif. , April 23, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation 
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2020 financial results on Thursday,
View HTML